Chiome Bioscience: Publication of a research publication using Tribody technology on cancer immunotherapy from Chiome Bioscience in collaboration with Ceinge

Publication of a research publication using Tribody™ technology on cancer immunotherapy

Chiome Bioscience in collaboration with Ceinge

The publication is published based on research using our Tribody™ technology. Tribody™ technology is one of our platform antibody engineering technologies that can generate multi-specific antibodies applicable to cancer immunotherapy. The research results are published in the International Journal of Molecular Sciences.

This research is being conducted in collaboration with Ceinge Biotecnologie Avanzate (“Ceinge”), a non-profit research consortium in Italy. We have constructed new bi-specific tribodies targeting different molecules involved in immune checkpoints. The tribody exhibited the retained binding activity to each target, increased immunomodulatory effect to induce lymphocyte activation, and enhanced in vitro cytotoxicity against tumor cells. Saloon™ format could also reduce production costs. Moreover, the molecular size is well suited for both tumor penetration and an acceptable half-life. Tribody could offer useful therapeutic applications, particularly in cancer patients resistant to monotherapy.

1. title ： Novel bi-specific immunomodulatory tribodies potentiate T cell activation and increase anti-tumor efficacy

Authors ： Margherita Passariello, Asami Yoshioka, Kota Takahashi, Shu-ichi Hashimoto, Rosa Rapuano Lembo, Lorenzo Manna, Koji Nakamura and Claudia De Lorenzo

Newspaper ： International Journal of Molecular Sciences

https://www.mdpi.com/1422-0067/23/7/3466

＜About Ceinge-Biotecnologie Avanzate＞

Ceinge is a non-profit consortium research organization in Naples, with entirely public capital, founded in 1983.

Ceinge operates in the field of molecular biology and advanced biotechnologies applied to human health. It is an excellence in Italy and abroad for the research and diagnosis of genetic diseases.

MT>

Tribody™ technology enables the generation of multispecific antibody products. This unique technology overcomes major shortcomings of conventional monospecific antibody formats as well as currently developed bispecific antibody formats. Tribody™ enables the creation of a unique antibody by building multi-binding sites that bind to different antigens or epitopes, which differentiate them from conventional antibodies. It is expected to generate antibodies against targets that could not be made into pharmaceuticals and to generate antibodies that can be released by combination drug therapy.